KMTS earnings analysis
What we found in KMTS's 10-K: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Kestra Medical Technologies (KMTS) reported substantial revenue growth for FY26, achieving $95.1 million, a 59% increase year-over-year, driven by a 58% increase in patient count. However, the net loss widened to $131.6 million due to escalating operational costs related to expanding sales and marketing efforts. The company anticipates significant investments in its Cardiac Recovery System platform amid a challenging healthcare reimbursement landscape, with FY27 revenue guidance at $137 million, representing a 44% growth compared to FY26.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Strong Revenue Growth
- Revenue increased 59% year-over-year to $95.1 million, driven by a 58% increase in the number of patients using the ASSURE WCD.
- Improved Gross Profit
- Gross profit rose to $48.9 million in FY26, up from $24.2 million in FY25, reflecting better cost management and increased patient utilization.
- Successful Fundraising
- Completed a public offering in December 2025, raising $149.3 million to support growth initiatives and operations.
- New Loan Facility
- Secured a $200 million loan facility on July 10, 2026, with $75 million funded immediately, bolstering liquidity.
- Future Orientation
- FY27 guidance anticipates revenue reaching $137 million, indicating a projected 44% growth over FY26.
- Expanding Sales Force
- Total number of territories increased from 80 to approximately 130, emphasizing growth in the sales force.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- High Operating Losses
- Net loss for FY26 reached $131.6 million, attributed to rising sales and operational expenses.
- Cash Flow Challenges
- Negative cash flows from operations totaled $81.7 million for FY26, raising concerns over liquidity management.
- Regulatory and Compliance Risks
- Failure to comply with healthcare regulations could hamper operations and result in significant penalties, impacting ongoing growth.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-2.43
- Gross margin
- 51.4%
- Operating margin
- -141.5%
What they said about what is next.
FY27 revenue guidance set at $137 million, reflecting expected growth.
The filing reads better than the one before it.
What came before.
- 10-Q · March 17, 2026
- Kestra Medical Technologies, Ltd. reported a revenue increase to $24.55 million for Q3 2026, up 63% YoY. Despite a rise in expenses, gross margin improved to 52.6%, although the company recorded an EPS loss of -0.61.…
- 10-Q · December 11, 2025
- Kestra Medical Technologies reported significant revenue growth in Q2 2026, with a 53% increase to $22.6 million compared to the same quarter last year, driven by a larger patient base. However, the company continues to…
- 10-Q · September 12, 2025
- Kestra Medical Technologies, Ltd. demonstrated improved financial performance in its Q1 2026 results, achieving a revenue of $19.37 million, which marked a 52% increase compared to the same period last year. The company…
- 10-K · July 17, 2025
- Kestra Medical Technologies, Ltd. reported significant growth in revenue of 115% year-over-year, reaching $59.8 million in 2025, driven largely by an increase in the patient base and improved reimbursement rates.…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing KMTS makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever